Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review

Yiming Chen¹ | Charline Magnin² | Jérome Brunelin³ | Edouard Leaune³ | Yiru Fang¹,4,5 | Emmanuel Poulet²,3

¹Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
²Department of Emergency Psychiatry, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
³INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, PSYR2 Team, University of Lyon, CH Le Vinatier, Lyon, France
⁴CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, China
⁵Shanghai Key Laboratory of Psychotic disorders, Shanghai, China

Correspondence
Yiru Fang, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Email: yirufang@aliyun.com

Funding information
National Basic Research Development Program of China, Grant/Award Number: 2016YFC1307100; Shanghai Mental Health Centre Clinical Research Center Special Project for Big Data Analysis, Grant/Award Number: CRC2018DSJ01-1; Sanming Project of Medicine in Shenzhen City, Grant/Award Number: TSZM201612006; National Natural Science Foundation of China, Grant/Award Number: 91232719 and 81771465; National Key Clinical Disciplines at Shanghai Mental Health Centre, Grant/Award Number: QMA-MH and 2011-873

Abstract

Background: Suicide is a major public health issue and the majority of those who attempt suicide suffer from mental disorders. Beyond psychopharmacotherapy, seizure therapies and noninvasive brain stimulation interventions have been used to treat such patients. However, the effect of these nonpharmacological treatments on the suicidal ideation and incidence of suicidality remains unclear. Here, we aimed to provide an update on the effects of seizure therapies and noninvasive brain stimulation on suicidality.

Methods: We conducted a systematic review of the literature in the PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Elsevier ScienceDirect, and Wiley Online Library databases using the MeSH terms “Electroconvulsive Therapy”, “Magnetic Seizure Stimulation”, “repetitive Transcranial Magnetic Stimulation”, “transcranial Direct Current Stimulation”, “Cranial Electrostimulation” and “suicide”. We included studies using seizure therapies and noninvasive brain stimulation as a main intervention that evaluated suicidality, regardless of diagnosis.

Results: Among 1,019 records screened, 26 studies met the inclusion criteria using either electroconvulsive therapy (n = 14), magnetic seizure therapy (n = 2), repetitive transcranial magnetic stimulation (n = 9), or transcranial direct current stimulation (n = 1). We observed that studies reported significant results, suggesting these techniques can be effective on the suicidal dimension of mental health pathologies, but a general statement regarding their efficacy is premature due to limitations.

Conclusions: Future enquiry is necessary to address methodological limitations and evaluate the long-term efficacy of these methods both alone and in combination with pharmacotherapy and/or psychotherapy.

Keywords
cranial electrostimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, suicide, transcranial direct current stimulation


1 | INTRODUCTION

According to the World Health Organization, suicide leads to approximately 800,000 deaths every year (WHO, 2019). The worldwide number of suicide attempts is even higher with a rate of 16 per 100,000 individuals, and based on data provided by the European Psychiatric Association, the rates of attempted suicides rate among males and females were 18 and 11 per 100,000, respectively (Plans et al., 2018). Every suicide is a tragedy for their families, communities, and entire countries for a long period. Suicides may occur throughout the lifespan and were the second leading cause of death among 15- to 29-year-olds in 2016. Suicide not only occurs in high-income countries, but it is also a global phenomenon in all regions of the world, with over 79% of the completed suicides occurring in low- and middle-income countries (WHO, 2019). Mental disorders, especially depression, are frequently found in the psychological reports of suicides in Asian as well as Western countries (Cheng et al., 2000; Phillips et al., 2002).

Given the high suicide risk of patients diagnosed with mental illnesses, it is important to track whether specific treatment strategies have the potential to rapidly and effectively reduce suicide risk. The common treatment approaches—such as pharmacotherapy and psychotherapy—have over years emerged as essential interventions reducing suicidality. However, lithium and ketamine, while effective, have various limitations such as drowsiness, dizziness, poor coordination, toxicity, and risk for dependency (Andrade, 2017; Zalsman et al., 2016). Regarding psychotherapy, a recent meta-analysis concluded that dialectical behavior therapy reduced self-directed violence and resulted in less psychiatric crisis interventions; however, it did not reduce suicidal ideation (DeCou et al., 2018). Therefore, to decrease suicidal ideation and prevent suicide attempts, other alternative or adjunct methods are warranted. Among them, seizure therapies and noninvasive brain stimulation methods have been proposed as possible interventional tools.

Seizure therapies such as electroconvulsive therapy (ECT), magnetic seizure therapy (MST), and noninvasive brain stimulation (NIBS) methods such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and cranial electrostimulation (CES) are under investigation (Desmyter et al., 2011). They may alleviate symptoms in several psychiatric conditions depending on the targeted psychiatric condition and application (Lefaucheur et al., 2014, 2017; Milev et al., 2016; Rosa & Lisanby, 2011; UK ECT Review Group, 2003). However, their efficacy on suicidality is still unclear. The aim of the present systematic review was to evaluate the effects of these applications on suicidality, that is, suicidal ideation, suicide attempt, and/or completed suicide.

2 | METHODS

2.1 | Search strategy and selection criteria

We performed a systematic review of the literature according to PRISMA guidelines (Liberati et al., 2009) including full-length original articles published in English and peer-reviewed journals until 1 June 2019. This systematic literature search was conducted in the PubMed, Cochrane Central Register of Controlled Trials, Elsevier ScienceDirect, and Wiley Online Library (STM) databases using a term list including words relative to ECT, MST, rTMS, tDCS, CES, and suicidality. We used words with combination of thesaurus [MeSH Terms] related to medical subject heading description, and [Other Term] related to keywords used in studies: (1) "Electroconvulsive Therapy" AND "suicide"; (2) "Magnetic seizure stimulation" AND "suicide"; (3) "repetitive Transcranial Magnetic Stimulation" AND "suicide"; (4) "Transcranial Direct Current Stimulation" AND "suicide"; (5) "Cranial Electrostimulation" AND "suicide".

Two independent investigators (YC and CM) screened the results according to the eligibility criteria, first on titles and abstracts and then on full-text articles. Eligibility criteria were as follows: (1) interventions designed for patients with a mental health disorder with available suicidality assessment as a main or secondary outcome; (2) seizure therapies (ECT and/or MST) and/or NIBS methods (rTMS and/or tDCS and/or CES) specified as the main interventions in acute or continuum phase; and (3) quality of the design corresponding to level 1, 2, or 3 on the Sackett scale. Duplicate articles and double search results were identified and removed throughout the search process.

2.2 | Data extraction and study quality assessment

Methods and results were extracted for each included article. We paid special attention to participant characteristics (sample size, diagnosis, treatment), study design, statistical analysis, and reported findings (immediately after treatment and long-term); next, we analyzed similarities and differences between articles with the aim of verifying which parameters were effective and for which mental disease.

Each study design was evaluated according to the modified Sackett Scale which is based on phyotheraphy evidence database (PEDro) scores for its level of evidence grade. The Sackett Scale involves 5 levels of evidence: level 1—high-quality randomized controlled trial (RCTs) (PEDro ≥6), divided into level 1a and 1b, based on the number of RCTs supporting the evidence; level 2—RCTs (PEDro score <6), cohort studies, and prospective controlled trials; level 3—case controls such as retrospective studies comparing conditions; levels 4 and 5—case reports, case series, uncontrolled pre–post-tests, and observational studies.

In addition, we referred to the grading of recommendations, assessment, development, and evaluations (GRADE) method to rate the quality of evidence. GRADE presents four grades as levels of evidence: high, moderate, low, and very low, considering different factors such as bias related to imprecision, inconsistency, publication, and indirectness of the study (Guyatt et al., 2011).

3 | RESULTS

The literature search retrieved 1,019 articles. After duplicates and double search results were removed and titles and abstracts were
assessed, 58 articles were selected for further evaluation. Among them, 26 studies met all inclusion criteria following full-text evaluation and were systematically analyzed. Due to the search results, George et al. (2014) included suicidal patients with mild traumatic brain injury was also accepted in our review. Berlim et al. (2014), Desmyter et al. (2016), and Hadley et al. (2011), were accepted as additional record identified through other sources by reading references of Weissman et al. (2018). Figure 1 shows the results of the search and selection process.

3.1 | Characteristics of studies

Fourteen ECT studies, two MST studies, nine rTMS studies, and one tDCS study were included in the present review. Among them, one nonblinded randomized trial involved therapeutic applications of both ECT and rTMS (Keshtkar et al., 2011) for major depressive disorder (MDD). There were other two nonblinded randomized trials which applied ECT for MDD (Kellner et al., 2005; Nordenskjöld et al., 2013), three prospective controlled studies for bipolar
disorder (Ciapparelli et al., 2001), for depressed elderly individuals (Veltman et al., 2018), and for depressive symptoms (Avery & Winokur, 1978). Eight retrospective studies of ECT for different kinds of mental illnesses were included (Ahmadi et al., 2015; Black et al., 1989; Brådvik & Berglund, 2006; Hunt et al., 2011; Liang et al., 2017; Munk-Olsen et al., 2007; Patel et al., 2006; Popiolek et al., 2018). Two prospective MST studies (Sun et al., 2016, 2018) were designed for patients with treatment-resistant depression (TRD). Five RCTs (Baeken et al., 2019; Desmyter et al., 2014, 2016; George et al., 2014; Weissman et al., 2018) and two prospective studies, Berlim et al. (2014) and Hadley et al. (2011) and using rTMS and deep transcranial magnetic stimulation (dTMS), respectively, and other two prospective studies (Croarkin et al., 2018; Wall et al., 2011) designed specifically for adolescents with suicidal ideation, were included. Only one RCT using tDCS was designed for patients with acute depressive episodes (Brunoni, Júnior, et al., 2013; Brunoni, Vallingo, et al., 2013).

The methodological quality of the six RCTs was high, five with a Sackett Scale level 1a (Baeken et al., 2019; Brunoni, Júnior, et al., 2013; Brunoni, Vallingo, et al., 2013; Desmyter et al., 2014, 2016; George et al., 2014), and the other one was rated as 1b (Weissman et al., 2018). However, Weissman et al. (2018) pooled data from two other published RCTs (Blumberger et al., 2011, 2016) which were all designed to compare the depressive remission rate by rTMS in patients with TRD and were guided by their own research team to measure suicidal ideations. Five ECT studies (Avery & Winokur, 1978; Ciapparelli et al., 2001; Kellner et al., 2005; Nordenskjöld et al., 2013; Veltman et al., 2018), two MST studies (Sun et al., 2016, 2018), and three rTMS studies (Berlim et al., 2014; Hadley et al., 2011; Wall et al., 2011) rated level 2 were designed as nonblinded randomized trials or prospective studies. The eight remaining ECT researches (Ahmadi et al., 2015; Black et al., 1989; Brådvik & Berglund, 2006; Hunt et al., 2011; Liang et al., 2017; Munk-Olsen et al., 2007; Patel et al., 2006; Popiolek et al., 2018) were all rated level 3. Overall, the level of evidence can be generally considered low, with only six studies out of twenty-six having an evidence level of 1.

### 3.2 | Participant characteristics

This review included twenty-six studies involving 3,589 patients diagnosed with different mental disorders: affective disorders (unipolar depression, bipolar disorder, or anxiety disorders) \( n < 3,710 \), post-traumatic stress disorder (PTSD) \( n = 92 \), personality disorders \( n = 2 \), mix mania \( n = 41 \), schizophrenia \( n = 50 \), schizoaffective disorders \( n > 60 \), and other nonaffective psychosis \( n = 9 \) or other disorders \( n = 48 \) referred to suicide. As for Avery & Winokur (1978) did not provide a clear description of participant diagnosis, we could not accurately calculate the sample of affective disorders and schizoaffective disorders. Heterogeneity was present among the participant demographics (Table 1).

### 3.3 | Intervention

#### 3.3.1 | Diagnostic tools

All the studies but two studies (Hadley et al., 2011; Hunt et al., 2011) used a diagnostic tool to select participants at baseline such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) \( n = 14 \), the International Statistical Classification of Diseases and Related Health Problems (ICD) \( n = 4 \), the Mini International Neuropsychiatric Interview (MINI) \( n = 7 \), or Antidepressant Treatment History Form (ATHF) \( n = 3 \). Only twelve studies provided clear exclusion criteria at baseline.

#### 3.3.2 | Stimulation protocol

Only half of the ECT studies described the treatment parameters. The parameters included features such as current, duration, frequency, and pulse width. Keshkdar et al. (2011) and Ciapparelli et al. (2001) used the MECTA Corporation model device (MECTA Corp, Lake Oswego, Ore) while Veltman et al. (2018), Ahmadi et al. (2015), and Patel et al. (2006) applied the Thymatron System IV (Somatics, Inc, Lake Bluff, Ill). Nordenskjöld et al. (2013) used the both. The only relevant variation concerning the frequency of sessions ranged between 1 session per month and 3 sessions per week. Technical characteristics of ECT are presented in Table 2.

MST intervention of these two studies was delivered with a MagPro MST machine (MagVenture) and a twin coil symmetrically placed over the frontal cortex with the maximal electric field over the Fz electrode position according to the international 10–20 system (DaSilva et al., 2011). Details are provided in Table 3. Intensity (expressed as % of the resting motor threshold (RMT)), frequency of stimulation, frequency of sessions, train duration and intertrain intervals, type of coil, and coil location are important parameters that influence the effects of rTMS. A large variability of these parameters was observed between studies, while a large majority of studies used high-frequency (10 Hz) rTMS with a figure 8 coil over the left dorsolateral prefrontal cortex (DLPFC). Desmyter et al. (2016) and Desmyter et al. (2014) used accelerated intermittent theta burst stimulation (iTBS), while Baeken et al. (2019) used placebo-accelerated iTBS. Blumberger et al. (2016) used bilateral stimulation (high-frequency rTMS over the left DLPFC, low-frequency rTMS – 1Hz over the right DLPFC), and Berlim et al. (2014) used deep TMS at 20Hz delivered with a “H1” coil over the left DLPFC. Intensity of stimulation varied across studies from 100% to 120% RMT. The total number of sessions varied from 7 to 30, while the frequency of sessions was 5 sessions per week at the lowest and 5 sessions per day at the highest. Details of rTMS parameters are provided in Table 4.

As outlined in Table 5, the only available tDCS study used a current density of 0.8 A/m² (2 mA/25 cm²) per 30 min/d using...
| Study                          | Sample (Stimulation group) | Diagnosis and diagnosis instruments                          | Male | Female | Mean age (SD) | Treatment                                                                 | Suicide characteristics compared | Medication                      |
|-------------------------------|-----------------------------|--------------------------------------------------------------|------|--------|---------------|---------------------------------------------------------------------------|-----------------------------------|----------------------------------|
| Kellner et al. (2005)         | 444                         | Unipolar MDD, DSM-IV, 24-HDRS≥21                             | 141  | 303    | 55.6 ± 16.8   | Bilfrontal ECT; Bilfrontal ECT+pharmacotherapy                           | Suicidal ideation of 24-HDRS      | Nortriptyline+lithium            |
| Brådvik and Berglund (2006)   | 195                         | Melancholia, DSM-IV and a multiaxial diagnostic schedule at discharge | /    | /      | /              | Pharmacotherapy; ECT; ECT+continuation treatment with antidepressants    | Suicidal gestures, occurrence of suicide attempt | Antidepressant pharmacotherapy |
| Liang et al. (2017)           | 487                         | Unipolar disorder or bipolar disorder, ICD−9-CM             | 174  | 313    | 38.5 ± 14.2   | ECT                                                                      | Completed suicide                 | Not specified                   |
| Ahmadi et al. (2015)          | 92                          | Both MDD and PTSD, DSM-IV and ICD                            | 78   | 14     | 52 ± 12       | Bilfrontal ECT                                                           | Completed suicide                 | Antidepressant monotherapy       |
| Keshtkar et al., 2011         | 40                          | MDD, DSM-IV                                                 | 21   | 52     | 35.6 ± 8.1    | Bilateral ECT, active rTMS                                               | Suicide ideation of BDI and HDRS  | Not specified                   |
| Patel et al. (2006)           | 30                          | Bipolar disorder, Major depression, Schizoaffective disorder, DSM-IV | 19   | 11     | 32.9 ± 11.3   | Bilateral ECT                                                           | Suicide ideation of 24-BPRS       | Psychotropic medications         |
| Ciapparelli et al. (2001)     | 64                          | Mixed mania and bipolar depression, DSM-IV                   | 40   | 24     | 38.0 ± 11.8   | Bilateral ECT                                                           | Suicide ideation of MADRS         | Lithium, anticonvulsants, TCAs, SSRIs, neuroleptics |
| Veltman et al. (2018)         | 89                          | Unipolar MDD, DSM-IV, MINI                                   | 30   | 59     | 73.4 ± 9.8    | Bilateral, unilateral ECT                                                | Suicidal ideation of MADRS        | Antipsychotics were tapered off before starting ECT but were allowed if clinically indicated |
| Hunt et al. (2011)            | 71                          | Affective disorder, schizophrenia, alcohol dependence, drug dependence, personality disorder, anxiety disorders, etc. | /    | /      | 54 (group received ECT at the time of death)                             | ECT                               | Completed suicide                 | Not specified                   |
| Munk-Olsen et al. (2007)      | 783                         | Schizophrenia, schizoaffective disorders, bipolar disorders, unipolar depressive disorders, other nonaffective psychosis, other disorders, ICD-8, and ICD-10 | /    | /      | /                | Bilateral, unilateral ECT                                                | Completed suicide                 | Not specified                   |

(Continues)
| Study                                           | Sample (Stimulation group) | Diagnosis and diagnosis instruments                                                                 | Male | Female | Mean age (SD)                  | Treatment                                                                 | Suicide characteristics compared                                      | Medication                                           |
|------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------|------|--------|-------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------|
| Popiolek et al. (2018)                         | 109                         | Bipolar depression, ICD-10                                                                        | /    | /      | /                            | cECT                                                                     | Suicide attempt or completed suicide                      | Not specified                                        |
| Black et al. (1989)                            | 372                         | Primary unipolar, secondary unipolar, bipolar depressives, DSM-III                                  | /    | /      | /                            | ECT, an adequate trial of antidepressants, an inadequate trial of antidepressants, a group receiving neither ECT nor antidepressants | Completed suicide                                      | Antidepressant monotherapy                           |
| Brunoni, Júnior, et al. (2013) and Brunoni, Valiengo et al. (2013) | 28                          | Major depression (single episode, recurrent, or bipolar), MINI-PLUS, MADRS, CGI                   | 28   | 28     | 52 ± 17 (ECT Plus Pharmacotherapy) 62 ± 13 (Pharmacotherapy alone) | cECT                                                                     | Suspected suicide and suicide attempt                  | Pharmacotherapy alone                                |
| Avery and Winokur (1978)                       | 257                         | Manic-depressive, depressed; manic-depressive, circular or mixed; psychotic depressive reaction; involutional melancholia; depressive neurosis; and schizoaffective, DSM-I or DSM-II | /    | /      | /                            | ECT, antidepressant therapy, and neither ECT nor antidepressants          | Suicidal ideation, suicide attempt and completed suicide | Imipramine, amitriptyline, desipramine, or nortriptiline |
| Sun et al. (2016)                              | 27                          | TRD, DSM-IV                                                                                       | 12   | 15     | 46.0 ± 15.3                  | MST                                                                      | Suicidal ideation of SSI                                      | Benzodiazepine medication                             |
| Sun et al. (2018)                              | 23                          | TRD, DSM-IV                                                                                       | 11   | 12     | 45.0 ± 12.2                  | MST                                                                      | Suicidal ideation of SSI                                      | Antidepressant, antipsychotic, benzodiazepine, lithium, pregabalin |
| Weissman et al. (2018)                         | 156                         | TRD, DSM-IV                                                                                       | 59   | 97     | 58.0 ± 12.5 (Bilateral) 48.9 ± 13.4 (Unilateral) 45.8 ± 13.4 (Sham) | Bilateral rTMS; L-DLPFC-rTMS and a sham control condition                 | Suicidal ideation of HDRS                                    | Not specified                                        |
| Wall et al. (2011)                             | 8                           | MDD, DSM-IV, CDRS-R ≥ 40                                                                          | 1    | 7      | 16.5                         | L-DLPFC-rTMS                                                             | Suicide ideation of the Suicide Severity Rating Scale      | SSRI                                                 |

(Continues)
| Study                          | Sample (Stimulation group) | Diagnosis and diagnosis instruments | Male | Female | Mean age (SD) | Treatment                                      | Suicide characteristics compared | Medication          |
|-------------------------------|----------------------------|--------------------------------------|------|--------|---------------|-----------------------------------------------|----------------------------------|---------------------|
| Hadley et al. (2011)          | 19                         | Depressive episode, BDI≥12           | 8    | 11     | 48 ± 16       | L-DLPFC-rTMS                                   | Suicidal ideation of SSI         | Not specified       |
| Desmyter et al. (2016)        | 50                         | TRD, MINI, 17-HDRS≥14                | 15   | 35     | 41.9 ± 11.77  | L-DLPFC iTBS-sham, sham-L-DLPFC iTBS           | Suicidal ideation of SSI         | No medication       |
| George et al. (2014)          | 41                         | Unipolar or bipolar depression, DSM-IV, SSIs≥12, 3 of HDRS≥3 | 35   | 6      | 42.5 ± 15.7   | L-DLPFC-rTMS, sham stimulation                | Suicidal ideation of SSI         | Not specified       |
| Desmyter et al. (2014)        | 12                         | TRD, MINI                            | 5    | 7      | 44.91 ± 10.8  | L-DLPFC iTBS, sham stimulation                | Suicidal ideation of SSI         | No medication       |
| Baeken et al. (2019)          | 45                         | MDD, MINI                            | 12   | 33     | 44 ± 19       | L-DLPFC iTBS-sham, sham-L-DLPFC iTBS           | Suicidal ideation of SSI         | No medication       |
| Croarkin et al. (2018)        | 19                         | TRD, ATHF                            | 6    | 13     | 16.0 ± 1.29   | L-DLPFC-rTMS                                   | Suicidal ideation of C-SSRS and CDRS-R | SSRI or SNRI        |
| Berlim et al. (2014)          | 17                         | MDD, MINI, 21-HAMD≥18                | 13   | 4      | 47.12 ± 13.26 | L-DLPFC DTMS                                   | Suicidal ideation of SSI         | Not specified       |
| Brunoni, Júnior, et al. (2013) | 120                        | Acute depressive episode, MINI       | 38   | 82     | 46.4 ± 14 (Placebo) | Sertraline-only, tDCS-only, combined-treatment, placebo | Suicide ideation of MADRS       | Sertraline, benzodiazepine |

Abbreviations: BPRS, Brief Psychiatric Rating Scale; ATHF, Antidepressant Treatment History Form; BDI, Beck Depression Inventory; CDRS-R, Children’s Depression Rating Scale-Revised; cECT, continuation ECT; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, IV Edition; DTMS, deep transcranial magnetic stimulation; HDRS, Hamilton depression scale; ICD, The International Statistical Classification of Diseases and Related Health Problems; iTBS, intermittent theta burst stimulation; L-DLPFC, Left dorsolateral prefrontal cortex; MADRS, Montgomery-Asberg Depression Rating Scale; MINI, The Mini International Neuropsychiatric Interview; MMSE, Mini-Mental State Examination; PTSD, post-traumatic stress disorder; rTMS, repetitive transcranial magnetic stimulation; SNRIs, Serotonin and Noradrenaline Reuptake Inhibitors; SSI, Beck Scale of Suicidal Ideation; SSI-CV, Beck Scale for Suicide Ideation-Chinese Version; SSRIs, Selective Serotonin Reuptake Inhibitors; TRD, treatment-resistant depression.
### TABLE 2 Summary of ECT study characteristics

| Study                        | Study design                        | Stimulus dose administration         | Number of sessions | Frequency of treatment | Analysis     | Primary Outcome | Results/Authors’ conclusions                                                                 | Evidence (PEDro) |
|------------------------------|-------------------------------------|--------------------------------------|--------------------|------------------------|--------------|-----------------|-----------------------------------------------------------------------------------------------|------------------|
| Kellner et al. (2005)        | A nonblinded randomized trial       | a Thymatron DGx device               | Treatment group: 13 sessions | ECT group             | Baseline, 1st w, 2nd w | 24-HDRS        | Expressed suicidal intent in depressed patients could be rapidly relieved with ECT.             | Level 1b         |
|                              |                                     |                                      | Control group: 3 sessions + PT (nortriptyline + lithium) | Acute phase | PT group | 1st w: 3 sessions | Occurrence of suicidal attempt: ECT < ATD. Seriousness of suicide attempt: ECT > ATD.            |                  |
|                              |                                     |                                      |                     |                        | 1st w: 3 sessions |                |                                                              |                  |
|                              |                                     |                                      |                     |                        | 2nd-5th w: 1 session/w |                |                                                              |                  |
|                              |                                     |                                      |                     |                        | 6th-13th w: 1 session/2 w |                |                                                              |                  |
|                              |                                     |                                      |                     |                        | The following 2 m: 1 session/m |                |                                                              |                  |
| Brådvik and Berglund (2006)  | A retrospective study               | Unknown                              | ECT group: at least 6 sessions | ECT group: 3 sessions/w | After 28 years and 32 years | / | Occurrence of suicidal attempt: ECT + continuation treatment with ATD < ECT < ATD. Seriousness of suicide attempt: ECT > ATD. | Level 3          |
|                              |                                     |                                      | ECT + continuation treatment with antidepressant group: 3 sessions/w during 2 weeks + continuation with ATD | ECT + continuation treatment with antidepressant group: 3 sessions/w during 2 weeks + continuation with ATD | / |                                                              |                  |
| Liang et al. (2017)          | A nationwide retrospective cohort study | Unknown                              | Unknown             | Unknown                | From 1 January 2000 to 31 December 2013 | / | Suicide events: ECT group < Non-ECT group Cumulative risk of suicide: ECT group < Non-ECT group (All patients with AD). Cumulative risk of suicide: ECT group < Non-ECT group (Patients with UD). Cumulative risk of suicide: ECT group = Non-ECT group (Patients with BD). | Level 3          |
| Ahmadi et al. (2015)         | A retrospective nested matched case-control study | A Thymatron IV ECT device            | 6 ± 1 sessions      | 3 sessions/week        | Baseline, 12th week | CGI-S, CGI-C | The suicide rate: 2.2% in ECT group and 5.9% in ATD group The relative-risk of suicidality was 64% less in MDD and PTSD with ECT treatment compared to those without ECT. | Level 3          |
| Study                        | Study design                  | Stimulus dose administration | Number of sessions | Frequency of treatment | Analysis                        | Primary Outcome | Results/Authors’ conclusions                                                                 | Evidence (PEDro) |
|------------------------------|-------------------------------|------------------------------|--------------------|------------------------|----------------------------------|-----------------|---------------------------------------------------------------------------------------------|------------------|
| Keshkar et al. (2011)        | A nonblinded randomized trial | ECT group: (MECTA Corporation model device) rTMS group: 90%RMT, Frequency: 10 Hz for either 2s or 6s, Train: 20s | 10 sessions (ECT or rTMS) | ECT group 3 sessions/w  rTMS group 1 session/d | Preintervention and postintervention | HDRS, BDI      | The decrease in the score of suicide in the short term: ECT > rTMS.                         | Level 1b         |
| Patel et al. (2006)          | A retrospective study         | A Thymatron System IV        | 5–10 sessions      | 3 sessions/w           | Pre-ECT and post-ECT             | 24-BPRS        | Efficacy of suicide for depressive patients: ECT > control group.                            | Level 3          |
| Ciapparelli et al. (2001)    | A prospective controlled study | MECTA Corporation model device | MM: 7.2 ± 1.7 sessions; BD: 7.3 ± 1.6 sessions | 2 sessions/w           | T0, T1, T2                       | MADRS, BPRS, CGI-S | The decrease in suicidality: MM > BD from T0 to T2.                                           | Level 2          |
| Veltman et al. (2018)        | A prospective controlled study | A Thymatron System IV        | 4 sessions         | 2 sessions/w           | Baseline, 1st w, 2nd w            | MADRS          | Suicidality showed significant improvement in w 1 as compared with baseline.               | Level 2          |
| Hunt et al. (2011)           | A retrospective study         | Unknown                      | Unknown            | Unknown                | In 2011                          | /               | The fall in the use of ECT has not affected suicide rates in patients receiving this treatment. | Level 3          |
| Munk-Olsen et al. (2007)     | A register-based cohort study | Unknown                      | Unknown            | Unknown                | In 2007                          | /               | Patients who had received ECT had a slightly higher suicide rate, especially within the first 7 days after the last ECT treatment. | Level 3          |
| Popiolek et al. (2018)       | A retrospective study         | Unknown                      | 5.8 ± 5.3 sessions | Unknown                | From January 2011 to December 2014 | /               | Patients treated with cECT had a similar risk of suicide attempt or completed suicide to those who did not receive cECT. | Level 3          |
| Study                          | Study design          | Stimulus dose administration | Number of sessions | Frequency of treatment | Analysis                      | Primary Outcome                                                                 | Results/Authors’ conclusions                                                                 | Evidence (PEDro) |
|-------------------------------|-----------------------|------------------------------|--------------------|------------------------|-------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------|
| Black et al. (2016)           | A retrospective study | Unknown                      | Unknown            | Unknown                | From January 1970 to December 1981 | From a short-term follow-up of depressives that ECT received in the hospital has minimal influence on subsequent mortality, including suicide. | Level 3                                                     |                  |
| Brunoni, et al. (2013)        | A multicenter nonblinded randomized trial | The Mecta Spectrum 5000Q device and a Thymatron System IV | 29 sessions        | Weekly cECT for 6 weeks and thereafter every 2 weeks for 46 additional weeks, a total of 29 ECTs for the full year. | The patients were recruited between 10 January 2008 and 22 March 2012. Follow-up was completed on 29 May 2012. | One suspected suicide and 3 suicide attempts by intoxication occurred, all in the PT-alone group. | Level 2          |                  |
| Avery and Winokur (1978)      | A prospective study   | /                            | Unknown            | Unknown                | From 1959 to 1960 and from 1967 to 1968 | Suicide attempts were seen significantly less frequently in the ECT groups than in the ATD group or the “adequate” ATD subgroup. Fewer suicide attempts occurred in the ECT group compared to the ATD group among both in those who had attempted suicide prior to admission (0% versus 10%) and in those who had not (1.1% versus 3.6%). | Level 2          |                  |

Abbreviations: AD, Affective disorders; ATD, Antidepressant; BD, Bipolar disorder; BDI, Beck Depression Inventory; 24-BPRS, 24-item Brief Psychiatric Rating Scale; CGI-C, Clinician Global Impressions-Change scale; CGI-S, Clinician-rated global illness severity; ECT, Electroconvulsive Therapy; HDRS, Hamilton depression scale; MADRS, Montgomery-Asberg Depression Rating Scale; MM, mixed mania; RCT, randomized controlled trial; T0, the day before starting ECT; T1, 48 hr after completion of the 3rd session; T2, a week after the last session; PEDro, the Physiotherapy Evidence Database tool; PT, pharmacotherapy; UD, unipolar disorder.
A standard commercial device (Chattanooga Ionto™ Dual Channel Devices, Chattanooga Group). The anode and the cathode were placed over the scalp areas corresponding, respectively, to the left and right DLPFC. tDCS was delivered 5 sessions per week for 2 weeks.

### 3.3.3 Associated therapies

Potential add-on treatments such as medication that can be delivered during the stimulation protocol were not specified in twelve studies (Berlim et al., 2014; George et al., 2014; Hadley et al., 2011; Hunt et al., 2011; Keshk et al., 2011; Liang et al., 2017; Munk-Olsen et al., 2007; Nordenskjöld et al., 2013; Popiolek et al., 2018; Sun et al., 2016, 2018; Weissman et al., 2018). In the studies from Baeken et al. (2019) and Desmyter et al. (2014, 2016) and, rTMS was given as a monotherapy. In other seven studies, participants were demanded to use the same type psychotropic medication to eliminate its medical effects on the outcomes. For instance, ECT was delivered together with antidepressant therapy as an experimental group in two studies (Brådvik & Berglund, 2006; Kellner et al., 2005). More precisely, participants in Wall et al. (2011)'s study only used selective serotonin reuptake inhibitor (SSRI) as an antidepressant. Only Brunoni, Júnior, et al. (2013) and Brunoni, Valiengo, et al. (2013)'s RCT used a fixed antidepressant dosage of 50mg/d of sertraline. In other studies, the medications were finally analyzed and compared with the stimulation group. For instance, Patel et al. (2006) designed a control group with psychotropic pharmacotherapy matched for age, sex, race, and diagnoses, while Ahmadi et al. (2015) included an antidepressant monotherapy group.

### 3.3.4 Sham stimulation

No sham-stimulation groups were included in the ECT or MST studies. Five rTMS studies (Baeken et al., 2019; Desmyter et al., 2014, 2016; George et al., 2014; Weissman et al., 2018) and the tDSC study (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013) were double-blind sham-controlled whereby both patients and investigators were blinded to the treatment allocations. In rTMS studies, the sham stimulation was administrated with the coil angled 90° away from the scalp in a single-wing tilt position producing some cutaneous sensation and similar sound intensity to that of active stimulation (Blumberger et al., 2011, 2016), or a specially designed commercial sham coil, exactly the same as the active coil in appearance, was placed on exactly the same target area of the scalp but without any active stimulation (Baeken et al., 2019; Desmyter et al., 2014, 2016; George et al., 2014). For the tDSC experiment, the sham method consisted of a brief (<30–60 s) period of active stimulation to mimic skin side effects such as tingling and itching before the simulated procedure.
| Study                  | Study design            | Stimulus dose administration | Number of sessions | Frequency of treatment | Analysis | Primary outcome | Results/Authors’ conclusions | Evidence (PEDro) |
|-----------------------|-------------------------|------------------------------|--------------------|------------------------|----------|-----------------|-------------------------------|------------------|
| Weissman et al. (2018)| RCT                     | Blumberger et al., 2011)     | 15 sessions        | 5 sessions/w           | Baseline, 1st w, 2nd w, 3rd w, 4th w, 5th w, 6th w | 24-HDRS           | Suicidal ideation: Bilateral > Sham | Level 1b         |
|                       | Left unilateral, Bilateral | Blumberger et al. (2016)     |                    |                        |          |                 | The difference between the left unilateral and sham was not significant. |                  |
|                       |                         |                              |                    |                        |          |                 | There was a modest correction between change in suicidal ideation and change in depression severity. |                  |
|                       | Age < 60y: 100% RMT, 10Hz, 30s intertrain intervals, 1,450 pulses/session | Age < 60y: 120% AdjRMT, 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session | 120% AdjRMT, 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session | 120% AdjRMT, R: 1Hz, L: 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session |          |                 | No difference in change in HDRS-16 score between suicide remitters and nonremitters. | Level 2           |
|                       | Age > 60y: 120% RMT, 10Hz, 30s intertrain intervals, 1,450 pulses/session | Age > 60y: 120% RMT, 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session | 120% AdjRMT, 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session | 120% AdjRMT, R: 1Hz, L: 10Hz, 30s intertrain intervals, R: 465, L: 750 pulses/session |          |                 |                              |                  |
| Wall et al. (2011)    | A prospective, open, multicenter study | 120% RMT, 10 Hz, 4-s train duration, 26-s intertrain interval, 75 trains, 3,000 pulses/session | 30 sessions        | 5 sessions/w           | Baseline, 10th session, 20th sessions, 30th sessions, 6th month | CDRS-R, 17QIDS-A, CGI-S, CGI-I, C-SSRS, SRQ, AEMF | Expression of suicidal ideation decreased as treatment progressed, commensurate with mood improvement. | Level 2           |
| Hadley et al. (2011)  | A prospective study     | 120% RMT, 10 Hz, 5-s train duration, 10-s intertrain intervals, 6,800 pulses/session | 10 sessions        | 5 sessions/w           | Baseline, after each session | BDI, SSI | Aggressive rTMS might be able to significantly and rapidly reduce suicidal ideation. | Level 2           |

(Continues)
| Study                  | Study design | Stimulus dose administration                                                                 | Number of sessions | Frequency of treatment | Analysis                                           | Primary outcome | Results/Authors' conclusions                                                                 | Evidence (PEDro) |
|-----------------------|-------------|-----------------------------------------------------------------------------------------------|--------------------|-----------------------|----------------------------------------------------|----------------|---------------------------------------------------------------------------------------------|------------------|
| Desmyter et al. (2016) | RCT         | 110% RMT, 50 Hz, 54 trains of 10 bursts of 3 stimuli/session, repeated every 200 ms, 1,620 pulses/session | 20 sessions          | 5 sessions/d          | Baseline, 1st w, 2nd w, 1st m, 6th m              | SSI, HDRS      | A significant decrease in suicide risk was unrelated to active or sham stimulation and unrelated to depression response, lasting up to 1 month. | Level 1a        |
| George et al. (2014)  | RCT         | 120% RMT, 10 Hz, 5-s train duration, 10-s intertrain intervals for 30 min, 6,000 pulses/session | 9 sessions          | 3 sessions/d          | Baseline, before, and after each rTMS session     | SSI, Subjective visual analog scale | A rapid antisuicidal effect by delivering high doses of left prefrontal rTMS over 3 days wasn't demonstrated. | Level 1a        |
| Desmyter et al. (2014) | RCT         | 100% RMT, 2-s train duration, 8-s intertrain interval, 1,620 pulses/session                     | 20 sessions          | 5 sessions/d          | Baseline, 1st w, 2nd w                           | 17-HDRS, SSI   | A significant decrease in SSI score over time was found; unrelated to active or sham stimulation. | Level 1a        |
| Baeken et al. (2019)  | RCT         | 110% RMT, 2-s train duration, 8-s intertrain interval, 1,620 pulses/session                   | 20 sessions          | 5 sessions/d          | Baseline, 1st w, 2nd w, 4th w                     | BDI, SSI       | Both active and sham aTBS resulted in prompt decreases in suicidal ideation. Placebo responses are related to higher cognitive processes resulting in suicidal ideation attenuation. | Level 1a        |
| Study            | Study design          | Stimulus dose administration                                                                 | Number of sessions | Frequency of treatment | Analysis                        | Primary outcome | Results/Authors' conclusions                                                                                                                                                                                                 | Evidence (PEDro) |
|-----------------|-----------------------|------------------------------------------------------------------------------------------------|--------------------|------------------------|--------------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Croarkin et al. (2018) | A prospective study   | 120% RMT, 10 Hz, 4-s train duration, 26-s intertrain interval, 3,000 pulses/session           | 30 sessions        | 3-5 sessions/week     | Baseline, after 10 sessions, 20 sessions, 30 sessions | CDRS-R, C-SSRS, CGI-S | The predicted odds of suicidal ideation significantly decreased over 6 weeks of acute TMS treatment without adjustments for illness (depression) severity. The magnitude of the decrease in the predicted odds of suicidal ideation across 6 weeks of treatment was attenuated nonsignificantly in subsequent analyses that adjusted for illness (depression) severity. | Level 2          |
| Berlim et al. (2014)    | A prospective study   | 100% RMT (1st w), gradually increased to 120% during the 2nd w, 20 Hz, 2-s train duration, 20-s intertrain interval, 3,000 pulses/session | 20 sessions        | 5 sessions/w          | Baseline, 5th w                  | 21-HDRS, 16-QIDS-SR, HAMA, BAI, CGI-S | Suicidality ratings were significantly improved by week 5.                                                                                     | Level 2          |

Abbreviations: Adj RMT, resting motor threshold adjusted for distance; AEMF, Adverse Event Monitoring Form; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; C-SSRS, Columbia Suicide Severity Rating Scale; DTMS, deep transcranial magnetic stimulation; HAMA, Hamilton Anxiety Rating Scale; HDRS, Hamilton depression scale; 17-HDRS, 17-item Hamilton depression scale; MADRS, Montgomery-Asberg Depression Rating Scale; RCT, randomized controlled trial; RMT, resting motor threshold; rTMS, repetitive transcranial magnetic stimulation; SRQ, Subjective Reaction Questionnaire; SSI, Beck Scale of Suicidal Ideation; SSI-CV, Beck Scale for Suicide Ideation-Chinese Version; 17-QIDS-A, 17-item Quick Inventory of Depressive Symptoms-Adolescent version; 16-QIDS-SR, 16-item Quick Inventory of Depressive Symptomatology—Self-Report.
3.3.5 | Duration

In the ECT experimental studies, the treatment lasted from 2 weeks (four sessions) for the shortest (Veltman et al., 2018) to 4 months (thirteen sessions) (Kellner et al., 2005) for the longest. The two MST studies did not indicate the accurate duration of experiment. In the rTMS studies, the duration varied from 3 days to 8 weeks and stimulation was delivered one session per day during 10 days in the tDCS protocol. Apart from four ECT studies (Hunt et al., 2011; Liang et al., 2017; Munk-Olsen et al., 2007; Patel et al., 2006) and two rTMS studies (Berlim et al., 2014; Croarkin et al., 2018), the other eight ECT studies, seven rTMS studies, and the only available tDCS study evaluated participants during follow-up ranging from weeks to years.

3.3.6 | Standardized evaluation

Seventeen studies focused on suicidal ideation as primary outcome for suicidality (Baeken et al., 2019; Berlim et al., 2014; Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013; Ciapparelli et al., 2001; Croarkin et al., 2018; Desmyter et al., 2014; Desmyter et al., 2016; George et al., 2014; Hadley et al., 2011; Kellner et al., 2005; Keshtkar et al., 2011; Patel et al., 2006; Sun et al., 2016, 2018; Veltman et al., 2018; Wall et al., 2011; Weissman et al., 2018), while two studies assessed suicide attempt (Avery & Winokur, 1978; Brådvik & Berglund, 2006) and five studies analyzed rate of completed suicide (Ahmadi et al., 2015; Black et al., 1989; Hunt et al., 2011; Liang et al., 2017; Munk-Olsen et al., 2007). Popiolek et al. (2018) evaluated suicide attempts and completed suicide at the same time. Nordenskjöld et al. (2013) simply calculated the amount of suspected suicide and suicide attempts.

Different standardized clinical scales to measure suicidal ideation were used across the studies. The Beck Scale of Suicidal Ideation (SSI) was applied in eight studies (Baeken et al., 2019; Berlim et al., 2014; Desmyter et al., 2014, 2016; George et al., 2014; Hadley et al., 2011; Sun et al., 2016, 2018). To assess the severity of suicide, and Croarkin et al. (2018) and Wall et al. (2011) used the Columbia Suicide Severity Rating Scale (C-SSRS). The third item of the Hamilton depression rating scale (HDRS) or the tenth item of the Montgomery–Asberg Depression Rating Scale (MADRS) were in studies to assess severity of suicidal ideation (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013; Ciapparelli et al., 2001; Keshtkar et al., 2011; Kellner et al., 2005; Veltman et al., 2018; Weissman et al., 2018). The nine ECT studies did not use any specific scale to measure suicidality but analyzed the occurrence of suicide attempts (Avery & Winokur, 1978; Brådvik & Berglund, 2006; Nordenskjöld et al., 2013; Popiolek et al., 2018), the severity of suicide attempt (Brådvik & Berglund, 2006), suicide events (Liang et al., 2017), and suicide rates (Ahmadi et al., 2015; Black et al., 1989; Hunt et al., 2011; Munk-Olsen et al., 2007; Popiolek et al., 2018).
A large number of studies also evaluated the severity of depression with various standardized scales: the 17 or 21-item HDRS (Berlim et al., 2014; Desmyter et al., 2014; Kellner et al., 2005; Weissman et al., 2018), the Beck Depression Inventory (BDI) (Baeken et al., 2019; Hadley et al., 2011; Keshtkar et al., 2011), the 10-item MADRS (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013; Ciapparelli et al., 2001; Nordenskjöld et al., 2013; Veltman et al., 2018), and the Children’s Depression Rating Scale–Revised (CDRS-R) (Croarkin et al., 2018; Wall et al., 2011). The 17-item Quick Inventory of Depressive Symptomatology–Adult version (QIDS-A17) and the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (16-QIDS-SR) were used as the combination of several of these scales or specific scale for adolescents (Berlim et al., 2014; Wall et al., 2011).

3.4 | Results on suicidality

3.4.1 | Results of ECT studies

Ten out of the fourteen ECT studies reported significant efficacy of ECT on suicidality. Five studies highlighted the beneficial effect of ECT on suicidal ideation (Ciapparelli et al., 2001; Kellner et al., 2005; Keshtkar et al., 2011; Patel et al., 2006; Veltman et al., 2018). Another retrospective study observed that ECT can reduce the occurrence of suicide attempts (Brådvik & Berglund, 2006), and suicide attempts were seen significantly less in the ECT group than in the pharmacotherapy-alone group (Avery & Winokur, 1978; Nordenskjöld et al., 2013). Two other papers reported the long-term effect of ECT on completed suicides (Ahmadi et al., 2015; Liang et al., 2017). Three ECT studies did not observe any beneficial effects of ECT on suicidality (Black et al., 1989; Hunt et al., 2011; Popiolek et al., 2018). The ECT study published by Munk-Olsen et al. (2007) described an increase in suicide rates in patients receiving ECT. They believed that the bias (confounding by indication) is a likely explanation for the moderately increased suicide risk among ECT patients in this study and the more marked increase shortly after treatment.

Suicidal ideation

Five studies reported the acute effects of ECT on suicidal ideation after acute treatment within 3 weeks (Kellner et al., 2005; Patel et al., 2006), within 1 week after two sessions (Veltman et al., 2018), and one month after approximately nine sessions (Ciapparelli et al., 2001), by evaluating, respectively, the suicide subscale of MADRS (Ciapparelli et al., 2001), and the 24-item Brief Psychiatric Rating Scale (24-BPRS) (Patel et al., 2006; Veltman et al., 2018). Within them, Kellner et al. (2005) randomly assigned participants whose condition remitted and remained remitted for one week without treatment, after an acute course of three bilateral ECT sessions for a 6-month continuative phase, to receive either continual ECT or continual nortriptyline-lithium treatment. The results showed that 38.2% of the patients had a score decrease from 3 or 4 to 0 at item 3 of the 24-HDRS after 1 week (3 ECT sessions), 61.1% after 2 weeks (6 ECT sessions), and 80.9% at the end of the course of treatment (9 ECT sessions). In addition, comparing the rapid antisuicidal effects with other NIBS like rTMS, Keshtkar et al. (2011) randomized 73 patients with MDD in two groups: one rTMS and one ECT group. After ten sessions, ECT led to greater depressive symptom reductions and suicidal behavior than ten sessions of rTMS, as evaluated by the BDI and HDRS.

Suicide attempt

Brådvik & Berglund (2006) collected 96 suicidal and 96 matched controls who were diagnosed as melancholia in the 1950s and 1960s; they principally analyzed the occurrence and severity of suicide attempts following up until 1998. By distinguishing 3 groups: 1) ECT only, 2) antidepressant pharmacotherapy group, and 3) ECT with continuous antidepressant treatment, they demonstrated a better effect of ECT than antidepressants on the occurrence of suicide attempts in a treatment course of at least six sessions (2 weeks). However, on the other hand, they found a worsening on the severity of suicide attempts. Nordenskjöld et al. (2013) saw one suspected suicide and three suicide attempts by intoxication occurred, all in the pharmacotherapy-alone group but none in ECT plus pharmacotherapy group, while Avery & Winokur (1978) indicated suicide attempts were seen significantly less frequently in the ECT groups (0.8%) than in the antidepressant group (4.2%) or the “adequate” antidepressant subgroup (7.0%).

Completed suicide

Liang et al. (2017) compared the cumulative incidence of suicide between ECT (n = 487) and non-ECT recipients (n = 1,948) over 13 years. They reported a superior antisuicidal effect of ECT in patients with unipolar disorder and bipolar depression with the adjusted HR present 0.79 (p = .041) and 0.805 (p = .046) exerted than non-ECT group. Another retrospective study with the median of 8 years of follow-up analyzed the death rate, suicide rate, and the relative suicide risk of 92 patients treated with ECT and 3,393 treated with antidepressant monotherapy. Both groups were diagnosed with both PTSD and MDD. The suicide rate was 2.2% and 5.9% in groups with and without ECT, respectively (Ahmadi et al., 2015).

There were some studies that failed to demonstrate that ECT had a preventative effect on suicide in the long term. According to a national clinical survey in England, Hunt et al. (2011) concluded that the reduction in ECT use did not influence suicide rates in patients who received this treatment by collecting an 8-year sample of suicide cases (1999–2006). Black et al. (1989) included from a short-term follow-up study of depressed individuals whom had received ECT in the hospital had minimal influence on suicide. And Popiolek et al. (2018) concluded by their 3-year follow-up study that patients treated with continuative ECT had a similar risk of suicide attempts or completed suicides to those who did not receive continuation ECT. Another striking findings by a cohort study demonstrated that 783 patients who received ECT had a slightly higher suicide rate (RR = 1.20) compared with 5,871 who had not, especially within the first 7 days from last ECT treatment (Munk-Olsen et al., 2007).
3.4.2 | Results of MST studies

Sun et al. (2016) and (2018) applied the same stimulation MST protocol and assessed the SSI to evaluate the suicidal ideation after 24 MST sessions, or until remission of depressive symptoms. Both trials reported significant reduction in suicidal ideation.

3.4.3 | Results of rTMS studies

Statistically significant effects of active rTMS on suicidal ideation were reported in four different studies (Berlim et al., 2014; Hadley et al., 2011; Wall et al., 2011; Weissman et al., 2018). Five studies revealed a beneficial, but nonsignificant effect, of active rTMS on suicidality over sham (Baeken et al., 2019; Croarkin et al., 2018; Desmyter et al., 2014, 2016; George et al., 2014).

Two studies from the same team highlighted the efficacy of left unilateral (10Hz) or bilateral (left: 1Hz; right: 10Hz) DLPFC rTMS on reducing depression in patients with TRD (Blumberger et al., 2011, 2016). Two years later, they integrated data from these two trials and determined that bilateral rTMS was superior to sham rTMS in reducing suicidal ideation in patients with TRD with a significant odds ratio (OR) = 3.03 after fifteen sessions over 3 weeks (Weissman et al., 2018). Another trial analyzing the evidence from nineteen adults with MDD explained that high-dose left DLPFC (L-DLPFC) rTMS of 120% RMT and 10 Hz might be a tolerated therapy to rapidly diminish suicidal ideation, as the suicidal ideation of 67% of patients diminished after only five sessions over 1 week (Hadley et al., 2011). Wall et al. (2011) also showed that suicidal ideation progressively decreased during thirty sessions of L-DLPFC high-frequency rTMS (10 Hz) in adolescents with TRD by using the same intensity of 120% RMT. Berlim et al (Berlim et al., 2014) applied 5 weeks of daily 20 Hz deep TMS in an open-labeled fashion in 17 depressed patients, showing improvement in suicidality ratings.

Similar to the results observed with ECT, inconsistencies in rTMS studies were also reported. Despite some studies reporting beneficial effects, some others failed to report any superiority of active rTMS over sham (Baeken et al., 2019; Croarkin et al., 2018; Desmyter et al., 2014; George et al., 2014).

3.4.4 | Results of tDCS study

This single tDCS RCT showed significant decreases in suicidal ideation. A significant decrease in suicidal thoughts measured by MADRS 10th item was observed after 10 daily tDCS sessions over sham ($p = .04$) (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013). This study suggests that patients with depression and suicidal ideation could benefit from tDCS.

4 | DISCUSSION

In the present review, we have examined the current status of ECT, MST, rTMS, and tDCS in the treatment of suicidal ideation, suicide attempts, and completed suicides.

Among the fourteen retrieved studies, five ECT experimental studies for MDD reported that patients who had received ECT showed significant faster and larger effects on suicidality than control patients groups (pharmacotherapy (Avery & Winokur, 1978; Nordskjöld et al., 2013; Kellner et al., 2005) or rTMS (Keshkik et al., 2011) or compared with baseline (Veltman et al., 2018). These findings are consistent with the recommendations of the Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder, whereby ECT considered a first-line treatment for acute suicidal ideation (Milev et al., 2016). A review (Sharma, 2001) of the role of ECT in suicide prevention also recommended the consideration of ECT in treatment algorithms to rapidly reduce suicide rates. The outcomes of these studies seem to be encouraging, and their level of evidence was relatively high (superior to PEDro level 2).

The eight other ECT studies are retrospective or observational studies investigating the occurrence of suicidal behavior in cohorts of patients who received ECT. With a PEDro level 3, their conclusions were less convincing than those from two RCTs and two prospective trials. Among them, three studies did not observe any influence of ECT on completed suicides and suicide attempts (Black et al., 1989; Hunt et al., 2011; Popiolek et al., 2018). The five other open studies showed a positive and significant antisuicidal effect of ECT. Nevertheless, neither Bergfeld et al. (2018) or Hunt et al. (2011) gave valuable explanations or assumptions to explain discrepancies observed between studies regarding the long-term effect of ECT in their meta-analyses. Difference may be due to the assumption that there is a relapse in depressive episodes, rather than “incomplete” recovery and psychomotor retardation after ECT, despite an expected good short-term effect on these symptoms (Brådvik & Berglund, 2004). Sharma, 2001 (Sharma, 2001) suggested that ECT had an acute, but not a long-term beneficial effect on suicidality. Unfortunately, only Nordskjöld et al. (2013) and Popiolek et al. (2018) designed or analyzed the efficacy of ECT as a maintenance approach for suicidality, but their conclusions were inconsonant. The lack of evidence on this aspect prevented the authors to systematically estimate its long-term influence. Considering these reasons, it was suggested to be very prudent to speculate on these findings given the high heterogeneity on long-term antisuicidal effects.

It is important to note that all the retrospective ECT studies have not investigated the influence of concomitant medication on suicidality. For instance, benzodiazepine could increase the clinical efficacy of ECT when delivered using bitemporal stimulation (Delamarre et al., 2019). Thus, it could modulate antisuicidal of ECT. Following this trend, possibly the best intervention for suicide should be to gather different approaches to maximize neuronal plasticity. Notwithstanding the limited and discordant evidence base for ECT in mood disorders, ECT remains a valuable therapeutic option with superior to PEDro level 2 to acutely reduce suicidal ideations. Continuative ECT treatment, including maintenance pharmacotherapy or psychotherapy, should be sustained during the long term to prolong the remission phase (Çakir & Çağlar, 2017).
4.2 | MST studies

The aims of Sun et al. (2016) and (2018) were to explore indicators or neuroplasticity of remission of suicidal ideation following MST. With the similar schedule as ECT, usually two to three times per week, an index course of twelve sessions (Milev et al., 2016), we could assume that these two studies evaluated the suicidal ideation at the baseline, and 2 or 3 months after the intervention. The results on suicidal ideation of participants with TRD were reasonable and logical because of its similarity with evidence level of 3 (Milev et al., 2016) but its overall recommendation especially in suicidality, needs to be further explored.

4.3 | rTMS studies

As observed with ECT studies, our review revealed inconsistencies across rTMS studies. Hence, four study effects with PEDro level over 2 concluded that rTMS may have an antisuicidal effect (Berlim et al., 2014; Hadley et al., 2011; Wall et al., 2011; Weissman et al., 2018) whereas four others (Baeken et al., 2019; Desmyter et al., 2014, 2016; George et al., 2014) did not observe a significantly superior antisuicidal effect of active stimulation over sham stimulation. Moreover, Baeken et al. (2019) concluded that sham-stimulation responses resulted in a greater effect on cognitive process involved in suicidal ideation than active. With a similar high-dose accelerated protocol, Desmyter et al. (2016) had a powerful evidence level of 1a. These negative and opposite results pushed us to consider the possible pitfalls. For instance, two studies evaluated differences between active and sham stimulation after 3 days of rTMS (George et al., 2014), or 3 days after the last iTBS (Desmyter et al., 2014). However, iTBS is thought to create more robust neuroplasticity effects that likely become evident later following treatment due to the recommended neurophysiology (Chung et al., 2014). The evaluation was likely done too soon to find a significant difference between these two groups. Regrettably, Desmyter et al. (2016) designed a crossover trial to evaluate the difference between these two groups after the first week of stimulation to avoid carryover effects that could be expected during the second week. They applied iTBS as an intervention; however, they failed to estimate its profound influence on suicidal ideation after the intervention. To confirm the placebo response, Baeken et al. (2019) reported a significant frontal polar perfusion decrease after 4 days of sham iTBS which was related to the attenuation of suicidal ideation. The assumption was that the placebo effects interfered with the final results, but they would only emerge in terms of the suicidal symptoms, but not the depression. Furthermore, due to a lack of meta-analysis specifically exploring the antisuicidal effects of rTMS, we have not successfully sought evidence of higher levels to appraise these findings.

Considering that this intervention was recommended by the U.S. Food and Drug Administration (FDA) for the treatment of resistant depression since 2014, accelerated DLPFC-rTMS is clinically acceptable and could be one of the therapeutic options in addition to its antidepressant effects. Thus, further research is necessary to extend to more naturalistic conditions, and larger sample to confirm its superior antisuicidal effect over sham.

4.4 | tDCS study

According to the one available study, tDCS could be a choice to decrease suicidality. Another study found that tDCS combined with sertraline was more effective than tDCS, or sertraline alone, on depression. Following this trend, probably the best treatment for suicide might be to combine different interventions, such as pharmacotherapy, to decrease suicidality of patients with depression (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013).

4.5 | Safety

In reference to safety, while both rTMS and tDCS are generally considered safe and acceptable if the appropriate guidelines and recommendations are followed, more research is needed to verify the safety parameters of rTMS and tDCS for the purpose of preventing suicidality. The adverse events of ECT potentially could be prevented. It is possible that the routine application of an ECT checklist could diminish the rates of adverse events.

4.6 | Limitations

Our aim was to evaluate the efficacy between five physical treatments (ECT, MST, rTMS, tDCS, and CES) on suicidality. Due to the limited number of studies and the high heterogeneity between protocols, we were not able to complete a quantitative synthesis and to undertake a meta-analysis. The efficacy of seizure therapies and NIBS as a continuous intervention also should be further explored as Nordenskjöld et al. (2013) and Popiolek et al. (2018) were the only two studies discussing the long-term effect of ECT as continuation treatment. None of the MST, rTMS, or tDCS studies investigated MST and/or rTMS and/or tDCS as a continuous intervention to assess its long-term influence after the acute course of intervention sessions. With a PEDro level of 3 in eight of them, a lack of control group, weak design, and possible cohort effects were obvious methodological shortcomings. Additionally, another obvious limitation of the present review constitutes selection bias. We restricted our search strategy to full-text articles in English. For example, a systematic review of Norwegian papers revealed doubt upon the efficacy of ECT in the prevention of suicide. We could not critically evaluate those articles or challenge the reported data. Moreover, as mentioned earlier, we had to exclude six studies whose Sackett Scale was equal or inferior to 4 (Brunoni, Júnior, et al., 2013; Brunoni, Valiengo, et al., 2013; Fligelman et al., 2016; Gambill & McLean, 1983; Kobeissi et al., 2011; Pan et al., 2018; Rapinesi et al., 2014); These case series
or uncontrolled pre-post-tests should also be recognized because of their values. Thirdly, impulsivity, anxiety, and irritability could often drive someone pondering suicide into action. Only George et al. reported greater improvements in anxiety and irritability with sham than with active TMS (George et al., 2014). These symptoms were lack of further evaluations and discussions as related phenotypes.

5 | CONCLUSION

Taking into consideration all the current evidence, we support the effect of ECT for acute suicidal ideation, but we cannot recommend the same regarding MST, rTMS, or tDCS. However, further research is necessary to determine whether there is any clear and persuasive evidence for the long-term efficacy of ECT on suicidality and to investigate the potentiation of ECT-elicited neuroplasticity changes targeting suicide theory. The antisuicidal effect of rTMS with a standard protocol needs to be confirmed. There is also a need for high-quality tDCS and CES trials designed for suicide. Combination therapy, both in short term and long term, could be a promising asset toward a faster and more sustained amelioration of suicide.

ACKNOWLEDGMENTS
This work was supported by the National Basic Research Development Program of China (grant numbers 2016YFC1307100); the Shanghai Mental Health Centre Clinical Research Center Special Project for Big Data Analysis (grant numbers CRC2018DSJ01-1); the Sanming Project of Medicine in Shenzhen City (grant numbers SZSM201612006); the National Natural Science Foundation of China (grant numbers 91232719, 81771465); and the National Key Clinical Disciplines at Shanghai Mental Health Centre (grant numbers OMA-MH, 2011-873). We are deeply grateful to all participants.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare. All authors contributed to and have approved the final submitted version of the manuscript.

AUTHOR CONTRIBUTION
Authors YC and CM were involved in the conception, design of the review, and screened the articles; Author YC analyzed the data and drafted the manuscript, figures, or tables under the guidance of CM and EP. Authors CM, EP, EL, and JB provided writing assistance and proof reading the article. All authors contributed to and have approved the final submitted version of the manuscript.

ETHICAL APPROVAL
All analyses were based on previous published studies; therefore, no ethical approval and patient consent are required.

PEER REVIEW
The peer review history for this article is available at https://publon ns.com/publon/10.1002/brb3.2144.

DATA AVAILABILITY STATEMENT
All data generated or analyzed for supporting the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Yiru Fang https://orcid.org/0000-0002-8748-9085

REFERENCES
Ahmadi, N., Moss, L., Simon, E., Nemeroff, C. B., & Atre-Vaidya, N. (2015). Efficacy and long-term clinical outcome of comorbid posttraumatic stress disorder and major depressive disorder after electroconvulsive therapy. Depression and Anxiety, 33(7), 640–647. https://doi.org/10.1002/da.22451
Andrade, C. (2017). Ketamine for depression, 1: Clinical summary of issues related to efficacy, adverse effects, and mechanism of action. Journal of Clinical Psychiatry, 78(4), e415–e419. https://doi. org/10.4088/JCP.17h11567
Avery, D., & Winnok, G. (1978). Suicide, attempted suicide, and relapse rates in depression. Archives of General Psychiatry, 35(6), 749–753. https://doi.org/10.1001/archpsyc.1978.0177030091010
Baeken, C., Wu, G.-R., & van Heeringen, K. (2019). Placebo aITBS attenuates suicidal ideation and frontopolar cortical perfusion in major depression. Translational Psychiatry, 9(1), 38. https://doi.org/10.1038/ s41398-019-0377-x
Bergfeld, I. O., Mantione, M., Figeè, M., Schuurman, P. R., Lok, A., & Denys, D. (2018). Treatment-resistant depression and suicidality. Journal of Affective Disorders, https://doi.org/10.1016/j.jad.2018.04.016
Berlim, M. T., Van den Eynde, F., Tovar-Perdomo, S., Chachamovich, E., Zangen, A., & Turecki, G. (2014). Augmenting antidepressants with deep transcranial magnetic stimulation (DTMS) in treatment-resistant major depression. The World Journal of Biological Psychiatry, 15(7), 570–578. https://doi.org/10.3109/15622975.2014.925141
Black, D., Winokur, G., Mohandoss, E., Woolson, R., & Nasrallah, A. (1989). Does Treatment Influence Mortality in Depressives?: A Follow-up of 1076 Patients with Major Affective Disorders. Annals of Clinical Psychiatry, 1(3), 165–173. https://doi.org/10.3109/10401 238909149975
Blumberger, D. M., Maller, J. J., Thomson, L., Mulsant, B. H., Rajji, T. K., Maher, M., Brown, P. E., Downar, J., Vila-Rodriguez, F., Fitzgerald, P. B., & Daskalakis, Z. J. (2016). Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: A randomized controlled study. Journal of Psychiatry & Neuroscience, 41(4), E58–E66. https://doi.org/10.1503/jpn.150265
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2011). A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. The World Journal of Biological Psychiatry, 13(6), 423–435, https://doi.org/10.3109/15622975.2011.579163
Brådvik, L., & Berglund, M. (2004). Suicide in severe depression related to treatment. European Archives of Psychiatry and Clinical Neuroscience, 255(4), 245–250. https://doi.org/10.1007/s00406-004-0553-7
Brådvik, L., & Berglund, M. (2006). Long-term treatment and suicidal behavior in severe depression: ECT and antidepressant pharmacother-apy may have different effects on the occurrence and seriousness of suicide attempts. Depression and Anxiety, 23(1), 34–41. https://doi. org/10.1002/da.20134
Brunoni, A. R., Júnior, R. F., Kemp, A. H., Lotufo, P. A., Benešor, I. M., & Fregni, F. (2013). Differential improvement in depressive symp-ptoms for tDCS alone and combined with pharmacotherapy: An ex-ploratory analysis from The Sertraline Vs. Electrical Current Therapy For Treating Depression Clinical Study. The International Journal of
Neuropsychopharmacology, 17(01), 53–61. https://doi.org/10.1017/S1461145703001065

Brunoni, A. R., Valiengo, L., Baccaro, A., Zanão, T. A., de Oliveira, J. F., Goulart, A., Boggio, P. S., Lotufo, P. A., Benseñor, I. M., & Fregni, F. (2013). The sertraline vs electrical current therapy for treating depression clinical study. JAMA Psychiatry, 70(4), 383. https://doi.org/10.1001/jamapsychiatry.32

Çakir, S., & Çağlar, N. (2017). Electroconvulsive therapy in the treatment of mood disorders: One-year follow-up. Noro Psikiyatri Arsi, 54(3), 196–201. https://doi.org/10.5127/npa.2016.14845

Cheng, A. T. A., Chen, T. H. H., Chen, C.-C., & Jenkins, R. (2000). Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. The Journal of ECT, 27(1), 18–25. https://doi.org/10.1097/YCT.0b013e3181e1a8c

Hadley, D., Anderson, B. S., Borckardt, J. J., Arana, A., Li, X., Nahas, Z., & George, M. S. (2011). Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression among the mentally ill in England: A national clinical survey. Psychiatry Research, 187(1–2), 145–149. https://doi.org/10.1016/j.psychres.2010.12.014

Kaye, S., Bewernick, B. H., Grubert, C., Hadrysiewicz, B. L., Axmacher, N., & Schlaepfer, T. E. (2011). Antidepressant effects of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. Journal of Psychiatric Research, 45(5), 569–576. https://doi.org/10.1016/j.jpsychires.2010.09.008

Kellner, C. H., Fink, M., Knapp, R., Petrides, G., Husain, M., Rummans, T., Mueller, M., Bernstein, H., Rasmussen, K., O’Connor, K., Smith, G., Rush, A. J., Biggs, M., McCleinton, S., Balline, S., & Malur, C. (2005). Relief of expressed suicidal INTENT by ECT: A consortium for research in ECT study. American Journal of Psychiatry, 162(5), 977–982. https://doi.org/10.1176/appi.ajp.162.5.977

Keshk, M., Ghanizadeh, A., & Firoozabadi, A. (2011). Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for the treatment of major depressive disorder, a randomized controlled trial. Journal of ECT, 27(4), 310–314. https://doi.org/10.1097/YCT.0b013e3282b31c31

Kobeissi, J., Aloysi, A., Tobias, K., Popeo, D., & Kellner, C. H. (2011). Resolution of severe suicidality with a single electroconvulsive therapy. The Journal of ECT, 27(1), 86–88. https://doi.org/10.1097/YCT.0b013e3181daa42a

Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, S., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., Devanne, H., Di Lazzaro, V., Filippović, S. R., Hummel, F. C., Jääskeläinen, S. K., Kimiskidis, V. K., Koch, G., Langbuth, G., Nyffeler, T., ... García-Larrea, L. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 125(11), 2150–2206. https://doi.org/10.1016/j.clinph.2014.05.021

Lefaucheur, J.-P., Antal, A., Ayache, S. S., Benninger, D. H., Brunell, J., Cogiamanian, F., Cotelli, M., De Ridder, D., Ferrucci, R., Langbuth, B., Marangolo, P., Mylius, V., Nitsche, M. A., Padberg, F., Palm, U., Poulet, E., Priori, A., Rossi, S., Schecklmann, M., ... Paulus, W. (2017). Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (TDCS). Clinical Neurophysiology, 128(1), 56–92. https://doi.org/10.1016/j.clinph.2016.10.087

Liang, C.-S., Chung, C.-H., Ho, P.-S., Tsai, C.-K., & Chien, W.-C. (2017). Superior anti-suicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. Bipolar Disorders, 20(6), 539–546. https://doi.org/10.1111/bdi.12589
Milev, R. V., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., Downar, J., Modirrousta, M., Patry, S., Vila-Rodriguez, F., Lam, R. W., MacQueen, G. M., Parikh, S. V., & Ravindran, A. V. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. The Canadian Journal of Psychiatry, 61(9), 561–575. https://doi.org/10.1177/0706743716660033

Munk-Olsen, T., Laursen, T. M., Videbech, P., Mortensen, P. B., & Rosenberg, R. (2007). All-cause mortality among recipients of electroconvulsive therapy. British Journal of Psychiatry, 190(05), 435–439. https://doi.org/10.1192/bjp.bp.106.026740

Nordenskjöld, A., von Knorring, L., Ljung, T., Carlberg, A., Brus, O., & Engström, I. (2013). Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression. The Journal of ECT, 29(2), 86–92. https://doi.org/10.1097/YCT.0b013e318276591f

Pan, F., Li, D., Wang, X., Lu, S., Xu, Y., & Huang, M. (2018). Neuronavigation-guided high-dose repetitive transcranial magnetic stimulation for the treatment of depressive adolescents with suicidal ideation: A case series. Neuropsychiatric Disease and Treatment, 14, 2675–2679. https://doi.org/10.2147/ndt.s176125

Patel, M., Patel, S., Hardy, D. W., Benzies, B. J., & Tare, V. (2006). Should electroconvulsive therapy be an early consideration for suicidal patients? The Journal of ECT, 22(2), 113–115. https://doi.org/10.1097/00124509-200606000-00007

Phillips, M. R., Yang, G., Zhang, Y., Wang, L., Ji, H., & Zhou, M. (2002). Risk factors for suicide in China: A national case-control psychological autopsy study. The Lancet, 360(9347), 1728–1736. https://doi.org/10.1016/S0140-6736(02)11681-3

Plans, L., Barrot, C., Nieto, E., Rios, J., Schulze, T. G., Papiol, S., Mitjans, M., Vieta, E., & Benabarre, A. (2018). Association between completed suicide and bipolar disorder: A systematic review of the literature. Journal of Affective Disorders, 242, 111–122. https://doi.org/10.1016/j.jad.2018.08.054

Popiolek, K., Brus, O., Elvin, T., Landén, M., Lundberg, J., Nordanskog, P., & Nordenskjöld, A. (2018). Rehospitalization and suicide following electroconvulsive therapy for bipolar depression—A population-based register study. Journal of Affective Disorders, 226, 146–154. https://doi.org/10.1016/j.jad.2017.09.030

Rapisini, C., Kotzalidis, G. D., Scatena, P., Del Casale, A., Janiri, D., Callovini, G., Piacentino, D., Serata, D., Raccah, R. N., Brugnoli, R., & Di Giacomantonio, V. (2014). Alcohol and suicidality: Could deep transcranial magnetic stimulation (dTMS) be a possible treatment? Psychiatria Danubina., 26(3), 281–284.

Rosa, M. A., & Lisanby, S. H. (2011). Somatic treatments for mood disorders. Neuropsychopharmacology, 36(1), 102–116. https://doi.org/10.1038/nnpp.2011.225

Sharma, V. (2001). The effect of electroconvulsive therapy on suicide risk in patients with mood disorders. The Canadian Journal of Psychiatry, 46(8), 704–709. https://doi.org/10.1177/070674370104600802

Sun, Y., Blumberger, D. M., Multant, B. H., Rajji, T. K., Fitzgerald, P. B., Barr, M. S., Downar, J., Wong, W., Farzan, F., & Daskalakis, Z. J. (2018). Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression. Transl Psychiatry, 8(1). https://doi.org/10.1038/s41398-018-0302-8

Sun, Y., Farzan, F., Multant, B. H., Rajji, T. K., Fitzgerald, P. B., Barr, M. S., Downar, J., Wong, W., Blumberger, D. M., & Daskalakis, Z. J. (2016). Indicators for remission of suicidal ideation following magnetic seizure therapy in patients with treatment-resistant depression. JAMA Psychiatry, 73(4), 337. https://doi.org/10.1001/jamapsychiatry.2015.3097

UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet, 361(9360), 799–808. https://doi.org/10.1016/s0140-6736(03)12705-5

Veltman, E. M., van Hulten, S., Twisk, J., Dols, A., van Exel, E., Stek, M. L., Sienaert, P., Bouckaert, F., van der Mast, R. C., & Rhebergen, D. (2018). Differences in speed of response of depressive symptom dimensions in older persons during electroconvulsive therapy. The Journal of ECT, 35(1), 35–39. https://doi.org/10.1097/YCT.0000000000000506

Wall, C. A., Courarkin, P. E., Sim, L. A., Husain, M. M., Janicak, P. G., Kozel, F. A., Emslie, G. J., Dowd, S. M., & Sampson, S. M. (2011). Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: A prospective, open pilot study. Journal of Clinical Psychiatry, 72(9), 1263–1269. https://doi.org/10.4088/JCP.11m07003

Weissman, C. R., Blumberger, D. M., Brown, P. E., Isserles, M., Rajji, T. K., & Downar, J. D. (2018). Bilateral repetitive transcranial magnetic stimulation decreases suicidal ideation in depression. The Journal of Clinical Psychiatry, 79(3), 17m11692. https://doi.org/10.4088/JCP.17m11692

WHO. (2019). Title of subordinate document. In: Suicide. Retrieved from http://www.who.int/news-room/fact-sheets/detail/suicide

Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Aresnens, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., Purebl, G., Kahn, J. P., Sáiz, P. A., Lipsicás, C. B., Bobes, J., Cozman, D., Hegerl, U., & Zohar, J. (2016). Suicide prevention strategies revisited: 10-year systematic review. The Lancet Psychiatry, 3(7), 646–659. https://doi.org/10.1016/S2215-0366(16)30030-X

How to cite this article: Chen Y, Magnin C, Brunelin J, Leaune E, Fang Y, Poulet E. Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review. Brain Behav. 2021;11:e02144. https://doi.org/10.1002/brb3.2144